ZYME

News Navigating 6 Analyst Ratings For Zymeworks

14d ago

News Zymeworks GAAP EPS of -$0.59 misses by $0.50

25d ago

Scanner Unusual buy pressure (8.4x avg, 71% up-volume, +6.7% / +1.63 intraday, above VWAP)

84d ago

News Zymeworks outlines $1.5B milestone potential and signals milestone-driven expansion strategy through 2028

91d ago

SEC filing ZYME Secures $250M Royalty-Backed Note, Retains 70% Royalties, Extends Cash Runway to 2028

92d ago

Insider trade Sale by Mark Hollywood

104d ago

News Zymeworks reports positive phase 3 Ziihera data; cash runway extended beyond 2028

141d ago

News Jazz Pharmaceuticals' Drug Extends Survival Past Two Years in Advanced Stomach Cancer Trial

145d ago

News Ziihera® (zanidatamab-hrii) Combinations Achieve Unprecedented Results in First-Line HER2+ Locally Advanced or Metastatic GEA including more than Two Years Median Overall Survival Benefit

146d ago

Insider trade Sale by Moore Paul Andrew (Chief Scientific Officer)

147d ago

Insider trade Sale by Galbraith Kenneth (Chair & CEO)

147d ago

Insider trade Sale by Smith Jeffrey T L (EVP & Chief Medical Officer)

147d ago

News Zymeworks Appoints Dr. Adam Schayowitz as Acting Chief Development Officer

153d ago

News Zymeworks to Report Third Quarter 2025 Financial Results and Host Conference Call on November 6, 2025

153d ago

News Zymeworks Announces Participation in Upcoming Investor Conferences

153d ago

News Form 8K Zymeworks Inc For: 30 December

153d ago

News Zymeworks shareholders elect directors and approve compensation at annual meeting

153d ago

News ETHZilla Makes Second Ether Sale, 2026 Crypto Regulation Expectations | Bloomberg Crypto 12/23/2025

160d ago

News Zephyrus Innovations™ announces US FDA 510(k) clearance for VaporShield™ CSTD

168d ago

News Juvare Acquires Zapoj Expanding Its Leadership in Critical Event Management and Visual Risk Intelligence

168d ago

News Zephyrus Innovations™ announces US FDA 510(k) clearance for VaporShield™ CSTD

168d ago